Iovance Biotherapeutics Inc (IOVA)

$2.36 -0.08 (-3.28%)
Market Cap 1.05B
Revenue (ttm) 164.07M
Net Income (ttm) -372.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -226.84%
Debt to Equity Ratio 0.00
Volume 15,735,801
Avg Vol 11,754,478
Day's Range N/A - N/A
Shares Out 396.97M
Stochastic %K 2%
Beta 0.76
Analysts Sell
Price Target $8.35

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanom...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 260 7120
Address:
825 Industrial Road, Suite 100, San Carlos, United States
Badgerkid
Badgerkid Feb. 6 at 2:16 AM
$IOVA Probably already posted, but just got back from the road: https://www.iovance.com/uploads/Karapetyan-et-al-Tandem-2026-3217-publication.pdf
0 · Reply
gorwell
gorwell Feb. 6 at 1:50 AM
$IOVA maybe not new information but I’m kind of glad that they’re finally releasing something that resembles PR’s now. We kind of need the Positive attention.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 6 at 1:49 AM
$CADL $IOVA $CATX we are stronger than ever before fundamentally!!!! Price always recovers … add if u can imho
0 · Reply
katanare
katanare Feb. 6 at 1:36 AM
$IOVA I get the frustration, but saying “good news gets completely invalidated” isn’t true. They can manipulate price action short-term, shake weak hands, and pin options… but they can’t erase real clinical data. If the signal is legit, institutions will eventually reprice it because they buy thesis, not candles. This is classic biotech behavior: dump it before the PR to scare retail, load cheaper, then let it run when positioning is set. We’ve seen this movie a hundred times. The only fair criticism is management being passive, but the data still matters. Price can be wrong for a while… not forever.
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Feb. 6 at 1:36 AM
$IOVA Really phenomenal results today on earlier stage previously treated advanced melanoma with anti-pd-1. It is definitely warranting best in class recognition ! Maybe we are not surprised given the depth & duration attributes of this therapy. Cannot help but wonder ( as always intake data with a rounded skepticism perspective ) : why again pre earnings, remember nsclc announcement pre Q3-25 earnings? Does it augur an almost match of low-end guidance or was it just a coincidence? Logically, cannot blame management for defending the stock amidst this garbage government policy, crypto scam meltdown & AI challenging software valuations. But cannot help but wonder. Lets see where earnings fall... anticipate the earnings call announcement in the next few days for the latter part of Feb. https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment
1 · Reply
katanare
katanare Feb. 6 at 1:29 AM
$IOVA People whining about ‘low patient count’ don’t understand how TIL works. This isn’t a pill trial where you enroll 500 overnight. TIL is manufactured patient-by-patient, tumor-by-tumor, and treatment is done sequentially. What matters is signal strength (ORR/DoR) and consistency across centers, not some inflated sample size. FDA has approved plenty of oncology therapies with smaller cohorts when the benefit is clear. If responses are real and durable, the market will reprice this fast.
2 · Reply
Hero2Zero
Hero2Zero Feb. 6 at 1:21 AM
$IOVA what do you expect? The market is made up of people. Just look at the reaction of many of the people who post here on the daily to the PR. People who are immersed in this company daily don’t even know the difference between a clinical trial and a retrospective study. Bitching about the quality of data, sample size, lack of registrational applicability - none of which is the point or in any way the purpose of this data. People are predominantly ignoramuses ergo the market (including the street) is predominantly driven by ignoramuses.
0 · Reply
stocksFRlife
stocksFRlife Feb. 6 at 1:21 AM
$IOVA there are lot of bashers here..cant take any positives, always trying to just spread negativity...not sure if they hold any IOVA shares currently, i believe they are in this board bcoz of FOMO and dosent want this is to be successful...
1 · Reply
ArtKatz
ArtKatz Feb. 6 at 1:17 AM
$IOVA they crushed this knowing this data would bring it up, they've done this over and over. The front run any good news by destroying the price and then the good news is totally negated. Totally corrupt and manipulated. MGMT is complient.
0 · Reply
katanare
katanare Feb. 6 at 1:13 AM
$IOVA That “shares available” chart doesn’t impress me at all. I’ve seen plenty of stocks with the exact same setup: millions of shares available to borrow, shorts get louder, push the price down, try to intimidate retail… and they still end up getting burned when the real catalyst hits. It’s the classic short playbook: show “infinite liquidity” to scare weak hands into selling. What matters way more is what we got today: strong positive data. That’s what changes the story — not a borrow availability number that swings around depending on brokers.
0 · Reply
Latest News on IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Jan 16, 2026, 5:15 PM EST - 20 days ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics: Bright Prospects For 2026

Dec 29, 2025, 12:51 AM EST - 5 weeks ago

Iovance Biotherapeutics: Bright Prospects For 2026

Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode

Nov 11, 2025, 1:24 PM EST - 3 months ago

Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode

Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 3:16 PM EST - 3 months ago

Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

Oct 29, 2025, 8:15 AM EDT - 3 months ago

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play

Oct 10, 2025, 10:30 AM EDT - 4 months ago

Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play

Iovance Biotherapeutics to Present at Upcoming Conferences

Aug 29, 2025, 8:30 AM EDT - 5 months ago

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25

Aug 21, 2025, 4:56 PM EDT - 6 months ago

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Aug 18, 2025, 4:15 PM EDT - 6 months ago

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:15 AM EDT - 6 months ago

Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Aug 7, 2025, 4:01 PM EDT - 6 months ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Here's why Iova stock surged 32% today and why the rally might not be over

Jul 23, 2025, 12:08 PM EDT - 7 months ago

Here's why Iova stock surged 32% today and why the rally might not be over

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

Jul 18, 2025, 12:02 PM EDT - 7 months ago

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

Jul 15, 2025, 7:30 AM EDT - 7 months ago

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Jul 14, 2025, 9:04 AM EDT - 7 months ago

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

Jul 14, 2025, 7:30 AM EDT - 7 months ago

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jul 11, 2025, 10:32 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 4:01 PM EDT - 7 months ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

Jul 10, 2025, 8:18 AM EDT - 7 months ago

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jul 3, 2025, 7:35 AM EDT - 7 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman

Jul 2, 2025, 5:46 PM EDT - 7 months ago

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 28, 2025, 7:46 AM EDT - 7 months ago

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

Jun 26, 2025, 4:45 PM EDT - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA

Jun 26, 2025, 9:00 AM EDT - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jun 24, 2025, 12:03 PM EDT - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 20, 2025, 9:07 AM EDT - 8 months ago

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman

Jun 18, 2025, 2:34 PM EDT - 8 months ago

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

Jun 18, 2025, 8:38 AM EDT - 8 months ago

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 16, 2025, 8:17 AM EDT - 8 months ago

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Badgerkid
Badgerkid Feb. 6 at 2:16 AM
$IOVA Probably already posted, but just got back from the road: https://www.iovance.com/uploads/Karapetyan-et-al-Tandem-2026-3217-publication.pdf
0 · Reply
gorwell
gorwell Feb. 6 at 1:50 AM
$IOVA maybe not new information but I’m kind of glad that they’re finally releasing something that resembles PR’s now. We kind of need the Positive attention.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 6 at 1:49 AM
$CADL $IOVA $CATX we are stronger than ever before fundamentally!!!! Price always recovers … add if u can imho
0 · Reply
katanare
katanare Feb. 6 at 1:36 AM
$IOVA I get the frustration, but saying “good news gets completely invalidated” isn’t true. They can manipulate price action short-term, shake weak hands, and pin options… but they can’t erase real clinical data. If the signal is legit, institutions will eventually reprice it because they buy thesis, not candles. This is classic biotech behavior: dump it before the PR to scare retail, load cheaper, then let it run when positioning is set. We’ve seen this movie a hundred times. The only fair criticism is management being passive, but the data still matters. Price can be wrong for a while… not forever.
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Feb. 6 at 1:36 AM
$IOVA Really phenomenal results today on earlier stage previously treated advanced melanoma with anti-pd-1. It is definitely warranting best in class recognition ! Maybe we are not surprised given the depth & duration attributes of this therapy. Cannot help but wonder ( as always intake data with a rounded skepticism perspective ) : why again pre earnings, remember nsclc announcement pre Q3-25 earnings? Does it augur an almost match of low-end guidance or was it just a coincidence? Logically, cannot blame management for defending the stock amidst this garbage government policy, crypto scam meltdown & AI challenging software valuations. But cannot help but wonder. Lets see where earnings fall... anticipate the earnings call announcement in the next few days for the latter part of Feb. https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment
1 · Reply
katanare
katanare Feb. 6 at 1:29 AM
$IOVA People whining about ‘low patient count’ don’t understand how TIL works. This isn’t a pill trial where you enroll 500 overnight. TIL is manufactured patient-by-patient, tumor-by-tumor, and treatment is done sequentially. What matters is signal strength (ORR/DoR) and consistency across centers, not some inflated sample size. FDA has approved plenty of oncology therapies with smaller cohorts when the benefit is clear. If responses are real and durable, the market will reprice this fast.
2 · Reply
Hero2Zero
Hero2Zero Feb. 6 at 1:21 AM
$IOVA what do you expect? The market is made up of people. Just look at the reaction of many of the people who post here on the daily to the PR. People who are immersed in this company daily don’t even know the difference between a clinical trial and a retrospective study. Bitching about the quality of data, sample size, lack of registrational applicability - none of which is the point or in any way the purpose of this data. People are predominantly ignoramuses ergo the market (including the street) is predominantly driven by ignoramuses.
0 · Reply
stocksFRlife
stocksFRlife Feb. 6 at 1:21 AM
$IOVA there are lot of bashers here..cant take any positives, always trying to just spread negativity...not sure if they hold any IOVA shares currently, i believe they are in this board bcoz of FOMO and dosent want this is to be successful...
1 · Reply
ArtKatz
ArtKatz Feb. 6 at 1:17 AM
$IOVA they crushed this knowing this data would bring it up, they've done this over and over. The front run any good news by destroying the price and then the good news is totally negated. Totally corrupt and manipulated. MGMT is complient.
0 · Reply
katanare
katanare Feb. 6 at 1:13 AM
$IOVA That “shares available” chart doesn’t impress me at all. I’ve seen plenty of stocks with the exact same setup: millions of shares available to borrow, shorts get louder, push the price down, try to intimidate retail… and they still end up getting burned when the real catalyst hits. It’s the classic short playbook: show “infinite liquidity” to scare weak hands into selling. What matters way more is what we got today: strong positive data. That’s what changes the story — not a borrow availability number that swings around depending on brokers.
0 · Reply
ArtKatz
ArtKatz Feb. 6 at 1:09 AM
$IOVA don't worry, they're ready to short this... seemingly that's all they do...
0 · Reply
katanare
katanare Feb. 6 at 1:08 AM
$IOVA IL-2 is basically the “boost” they give after Amtagvi. The TILs are the soldiers going after the tumor, and IL-2 is what fires them up, helps them multiply, and keeps them active so they can hit harder. The good part is we’re seeing Amtagvi can still work even with fewer IL-2 doses… meaning less punishment for the patient, and the treatment still delivers.
0 · Reply
E_Wallstreet
E_Wallstreet Feb. 6 at 1:03 AM
$IOVA Dan killin it … Fred taking a back seat …! Interesting that they quoted Dan.
0 · Reply
Brad9s
Brad9s Feb. 6 at 12:56 AM
$IOVA The guy speaking today was with Moffet out of Tampa. In Florida, there are 4 treatment centers. Pretty sure that study was representative of the state of Florida.
1 · Reply
Hazzzzy
Hazzzzy Feb. 6 at 12:51 AM
$IOVA Rothbaum and management must have really pissed off some big players in pharma and the investment space. Nothing seems to move the needle. I’m hoping ER does it, but I have my doubts. We’ll get there eventually but man this has been a frustrating ride as an investor.
1 · Reply
AlexRo777
AlexRo777 Feb. 6 at 12:29 AM
$IOVA so they said that the conference will be bullish but nothing can move Iovance?!
0 · Reply
quietpiggy
quietpiggy Feb. 6 at 12:19 AM
$IOVA I’ve seen more PR in the last month about this guy and his cancer experiments on fucking mice than I have ever seen on IOVA and their real world therapy - wtf!!!
0 · Reply
quietpiggy
quietpiggy Feb. 6 at 12:16 AM
$IOVA how do expect them to keep funding these printouts without diluting us to death? That is the short thesis by the way - they are well aware the science works and saves lives but they keep pressure on the share price so IOVA cannot raise funding via ‘at the market offerings’ - Truly disgusting!!
1 · Reply
ducruacuteo11
ducruacuteo11 Feb. 6 at 12:10 AM
$IOVA Freaking this stock is cursed. The day that they came out with good news, the market crashed. Unbelievable. We need to start praying for them. LOL. If the market crashes 20 to 30%, will this be at $1 like GS forecasted last year. Argh...
1 · Reply
quietpiggy
quietpiggy Feb. 6 at 12:07 AM
$IOVA this has to be a big catalyst. I am very surprised share price isn’t flinching
0 · Reply
DGANG3
DGANG3 Feb. 6 at 12:00 AM
$IOVA Wall Street just doesn't get it. If they do not understand that BP is talking to IOVA, then they need to find new jobs! This therapy , along with other cell related cancer treatments is the future.
0 · Reply
E_Wallstreet
E_Wallstreet Feb. 5 at 11:58 PM
$IOVA TIL-301 crossover numbers will be very interesting data…!
0 · Reply